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Host Genes and HIV Infection:
Implications and Applications
Disease emergence often involves the intro-
duction of a familiar microbial agent into a novel
ecologic niche or the evolution of a previously
unrecognized microorganism in what had osten-
sibly been a stable environment. So accustomed
are we to emergence brought on by changes in an
agent or its environment that we overlook effects
of the third force of causality—the host. The easy
justification for our relative indifference to the
contributions of the host has been that host cha-
racteristics, especially those under genetic regula-
tion,  have less potential for rapid, epidemio-
logically significant evolution; moreover, the gene-
tic mechanisms of host response have been too
poorly elucidated to permit rational manipulation.
The emergence of human immunodeficiency
virus (HIV), however, has been different. HIV has
“emerged” so masterfully by exploiting funda-
mental vulnerabilities in the immune system of
primates that contributions of host immunity can-
not be ignored. The virus has apparently evolved
from its simian cousins toward a form that is
extraordinarily well adapted to humans in seve-
ral ways: 1) it rapidly replicates, ensuring high
mutation rates within an individual host; 2) it is
readily transmissible from person to person in
the absence of an animal vector; and 3) because it
is not invariably lethal before the age span for
most human reproduction, evolutionary pressure
toward radical change, attenuation, or disap-
pearance from the population is not strong. The
enormous epidemiologic implications of these
basic facts have become obvious during the
decade and a half of our struggle against the
virus. We cannot control it by manipulating its
macroenvironment as we might a parasite carried
by a vector or waterborne virus. Interrupting
local transmission by setting up psychosocial or
mechanical barriers has limited potential. Despite
the recent highly encouraging advances in
antiretroviral therapy, direct and complete phar-
macologic or immunologic eradication of the
virus worldwide is still an untenable prospect. So
we have little choice but to search for biologic
strategies that reliably interdict the host-virus
relationship; to accomplish that will require
insight into the fundamental mechanisms of that
interaction—knowledge at the level of viral and
host genetics. Indeed, modulating genetically
determined features of the immune response to
the virus may represent the best hope for its
ultimate conquest. Recent breakthroughs have
accelerated the accumulation of the knowledge
necessary to accomplish that aim. In this issue of
Emerging Infectious Diseases, the review of
current information by McNicholl and colleagues
about the genetics of virus-host interaction
concentrates on the recently described variations
in genes encoding the human b-chemokine recep-
tors, appropriately providing perspectives from
both laboratory and public health sciences.
The quest to identify immunogenetic deter-
minants of the host-virus interaction in HIV
infection actually began with studies of the human
major histocompatibility complex (HLA) soon
after the AIDS epidemic was recognized, but in
the past 2 years molecular technology has been
focused on promising loci in the chemokine receptor
gene systems, as well as in HLA. The importance
of polymorphic variants of these host genes in
determining whether the infection occurs and
how rapidly it proceeds has been established.
The extreme polymorphism and other related
properties of HLA have made it more difficult
than expected to demonstrate the full influence of
products of these genes on the initiation and
progression of HIV infection; however, current
work on HLA is slowly confirming that expec-
tation, which is reasonably based on 25 years of
research on the role of antigen-presenting genes
in a whole range of autoimmune, inflammatory,
and infectious processes. In contrast, b-chemokines
and the genetically mediated variation in their
receptors were recognized only recently, but
the initial observations and numerous
confirmatory reports of their involvement in
HIV infection have been compelling, and there
is undoubtedly more  to come.
The most important consequence of these
recent discoveries has been to foster an
aggressive academic and industrial enterprise
aimed at developing a safe, clinically beneficial
immunomodulation of b-chemokines and their
receptors in both infected and uninfected per-
sons. The relative simplicity of the gene system,
the frequency of the apparently protective
variant (i.e., the 32bp deletion) of CCR5, and the
seemingly nonessential nature of either the wild
or mutant form of the receptor for normal
immune function have suggested that emulation
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the normal receptor with a specific high affinity
chemokinelike antibody) might interrupt viral
penetration and replication. The implication here
is clear. If antibodies to the normally functioning
CCR5 can block viral attachment and prevent
infection of the cell most critical to propagation of
the agent without collateral damage to vital host
immune function, a vaccine capable of inducing
those antibodies without serious adverse effects
could represent an adjunct to the current anti-
retroviral therapeutic agents and a major break-
through toward a primary preventive strategy
not dependent on changing personal behavior.
The optimism and publicity that often accompany
this kind of success must be tempered with caution:
the strategy depends heavily on whether HIV can
circumvent this hurdle by utilizing CXCR4 or
other alternative pathways of entry into cells.
However, even if the promise of preventive
and therapeutic intervention based on chemokine
receptor manipulation is not soon fulfilled, another
tangible benefit inherent in the discovery of
factors like the receptor variants and HLA
polymorphisms should not be overlooked. These
genetic factors, however amenable or resistant to
clinical manipulation they may prove to be, have
true prognostic value and therefore offer a clear,
immediate opportunity to refine our ongoing
evaluations of other promising therapeutic or
preventive measures. Consider the randomized
trial of a new chemotherapeutic agent, inten-
tionally designed to compare its average efficacy
in all trial participants with the average efficacy
of the conventional agent. Because HIV-1–infec-
ted persons who are heterozygous for the CCR5-
deletion progress more slowly than those who
carry only the wild type, stratifying the study
population according to the presence or absence
of the deletion, either during randomization or
during analysis, should clarify whether the
benefit of the experimental regimen in study
participants who also carry the more favorable
genetic trait is additive or even synergistic. More-
over, in clinical settings other than randomized
trials, the additional information about receptor
deletion status may be essential to analyzing the
effects of interventions under evaluation or to
customizing patient care.
The possibility that the genotype information
might be used to refine the observations from
current clinical research and to individualize the
management of HIV-infected or even uninfected
persons has also raised questions about whether
typing more routinely might be appropriate.
Although the concept of identifying a predisposing
factor and modifying recommendations for treat-
ment or prophylaxis accordingly is well established
in the management of infectious diseases,
screening for a particular genetic trait is not. So
another implication of the research on host
genetics in HIV infection is that it will probably
draw health professionals into many of the same
opportunities, obligations, and ultimately contro-
versies that already surround the discovery of
genes predisposing to cancer or chronic metabolic
diseases like hemochromatosis. What may distin-
guish genetic screening in the context of infec-
tious diseases from the rest, and even impose
greater urgency for decisions about genetic
testing, is that carriers of a genetic trait confer-
ring relatively high risk may be readily capable of
taking explicit precautions to avoid  exposure to
an identifiable etiologic agent. In short, in some
situations the payoff may be more immediate.
The discovery of host genes that exert major
influence on the acquisition and progression of
HIV infection has radically altered our thinking
about the pathogenesis of retroviral infection.
The prognostic value of these genetic factors
should be incorporated into the assessment of
interventions to control the infection. The intense
effort under way to translate knowledge of these
human genetic traits into clinical benefit for HIV-
infected and uninfected persons reflects a new
rationale for research on emerging infectious
diseases: consider the host, as well as the agent
and the environment.
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